TOX is a critical regulator of tumour-specific T cell differentiation.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
07 2019
Historique:
received: 18 05 2018
accepted: 04 06 2019
pubmed: 18 6 2019
medline: 1 10 2019
entrez: 18 6 2019
Statut: ppublish

Résumé

Tumour-specific CD8 T cell dysfunction is a differentiation state that is distinct from the functional effector or memory T cell states

Identifiants

pubmed: 31207604
doi: 10.1038/s41586-019-1324-y
pii: 10.1038/s41586-019-1324-y
pmc: PMC7698992
mid: NIHMS1531023
doi:

Substances chimiques

High Mobility Group Proteins 0
Homeodomain Proteins 0
Receptors, Antigen, T-Cell 0
Rhox8 protein, mouse 0
TOX protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

270-274

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI054977
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK058404
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA158069
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA172371
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR070234
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA209975
Pays : United States
Organisme : NCI NIH HHS
ID : DP2 CA225212
Pays : United States

Références

Thommen, D. S. & Schumacher, T. N. T cell dysfunction in cancer. Cancer Cell 33, 547–562 (2018).
doi: 10.1016/j.ccell.2018.03.012
Baitsch, L. et al. Exhaustion of tumor-specific CD8
doi: 10.1172/JCI46102
Schietinger, A. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389–401 (2016).
doi: 10.1016/j.immuni.2016.07.011
Mognol, G. P. et al. Exhaustion-associated regulatory regions in CD8
doi: 10.1073/pnas.1620498114
Philip, M. et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545, 452–456 (2017).
doi: 10.1038/nature22367
Henning, A. N., Roychoudhuri, R. & Restifo, N. P. Epigenetic control of CD8
doi: 10.1038/nri.2017.146
Stahl, S. et al. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma. Immunol. Lett. 123, 31–37 (2009).
doi: 10.1016/j.imlet.2009.01.011
Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8
doi: 10.1038/nri3307
O’Flaherty, E. & Kaye, J. TOX defines a conserved subfamily of HMG-box proteins. BMC Genomics 4, 13 (2003).
doi: 10.1186/1471-2164-4-13
Aliahmad, P. & Kaye, J. Development of all CD4 T lineages requires nuclear factor TOX. J. Exp. Med. 205, 245–256 (2008).
doi: 10.1084/jem.20071944
Aliahmad, P., Seksenyan, A. & Kaye, J. The many roles of TOX in the immune system. Curr. Opin. Immunol. 24, 173–177 (2012).
doi: 10.1016/j.coi.2011.12.001
Seehus, C. R. et al. The development of innate lymphoid cells requires TOX-dependent generation of a common innate lymphoid cell progenitor. Nat. Immunol. 16, 599–608 (2015).
doi: 10.1038/ni.3168
Page, N. et al. Expression of the DNA-binding factor TOX promotes the encephalitogenic potential of microbe-induced autoreactive CD8
doi: 10.1016/j.immuni.2018.04.005
Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 15, 486–499 (2015).
doi: 10.1038/nri3862
Schietinger, A. & Greenberg, P. D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35, 51–60 (2014).
doi: 10.1016/j.it.2013.10.001
Bloom, M. B. et al. Identification of tyrosinase-related protein 2 as a tumour rejection antigen for the B16 melanoma. J. Exp. Med. 185, 453–459 (1997).
doi: 10.1084/jem.185.3.453
Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8
doi: 10.1084/jem.20030590
Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell 176, 775–789 (2019).
doi: 10.1016/j.cell.2018.11.043
Simoni, Y. et al. Bystander CD8
doi: 10.1038/s41586-018-0130-2
West, E. E. et al. Tight regulation of memory CD8
doi: 10.1016/j.immuni.2011.05.017
Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8
doi: 10.1016/j.immuni.2015.01.006
Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472–484 (2005).
doi: 10.1038/nri1632
Man, K. et al. Transcription factor IRF4 promotes CD8
doi: 10.1016/j.immuni.2017.11.021
Scott-Browne, J. P. et al. Dynamic changes in chromatin accessibility occur in CD8
doi: 10.1016/j.immuni.2016.10.028
Flanagan, W. M., Corthésy, B., Bram, R. J. & Crabtree, G. R. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352, 803–807 (1991).
doi: 10.1038/352803a0
Jain, J. et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 365, 352–355 (1993).
doi: 10.1038/365352a0
Staveley-O’Carroll, K. et al. In vivo ligation of CD40 enhances priming against the endogenous tumour antigen and promotes CD8
doi: 10.4049/jimmunol.171.2.697
Wang, Q., Strong, J. & Killeen, N. Homeostatic competition among T cells revealed by conditional inactivation of the mouse Cd4 gene. J. Exp. Med. 194, 1721–1730 (2001).
doi: 10.1084/jem.194.12.1721
Wherry, E. J. et al. Molecular signature of CD8
doi: 10.1016/j.immuni.2007.09.006
Brockstedt, D. G. et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc. Natl Acad. Sci. USA 101, 13832–13837 (2004).
doi: 10.1073/pnas.0406035101
Sinnathamby, G. et al. Priming and activation of human ovarian and breast cancer-specific CD8
doi: 10.1097/CJI.0b013e3181b0b125
Espinosa-Carrasco, G. et al. Systemic LPS translocation activates cross-presenting dendritic cells but is dispensable for the breakdown of CD8
doi: 10.1371/journal.pone.0130041
Zhang, N. & Bevan, M. J. TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat. Immunol. 13, 667–673 (2012).
doi: 10.1038/ni.2319
Hartley, S. W. & Mullikin, J. C. QoRTs: a comprehensive toolset for quality control and data processing of RNA-seq experiments. BMC Bioinformatics 16, 224 (2015).
doi: 10.1186/s12859-015-0670-5
Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer New York, 2009).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
doi: 10.1093/bioinformatics/bts635
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
doi: 10.1093/bioinformatics/btt656
Harrow, J. et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 22, 1760–1774 (2012).
doi: 10.1101/gr.135350.111
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
doi: 10.1093/bioinformatics/btp324
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
doi: 10.1093/bioinformatics/btp352
Liu, T. Use model-based Analysis of ChIP–seq (MACS) to analyze short reads generated by sequencing protein–DNA interactions in embryonic stem cells. Methods Mol. Biol. 1150, 81–95 (2014).
doi: 10.1007/978-1-4939-0512-6_4
Ramírez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res. 44, W160–165 (2016).
doi: 10.1093/nar/gkw257
Martin, Marcel. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10–12 (2011).
doi: 10.14806/ej.17.1.200
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
doi: 10.1186/gb-2009-10-3-r25

Auteurs

Andrew C Scott (AC)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.

Friederike Dündar (F)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.

Paul Zumbo (P)

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.
Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.

Smita S Chandran (SS)

Parker Institute for Cancer Immunotherapy, New York, NY, USA.
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Christopher A Klebanoff (CA)

Parker Institute for Cancer Immunotherapy, New York, NY, USA.
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weill Cornell Medical College, New York, NY, USA.

Mojdeh Shakiba (M)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.

Prerak Trivedi (P)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Laura Menocal (L)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.

Heather Appleby (H)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Steven Camara (S)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Dmitriy Zamarin (D)

Parker Institute for Cancer Immunotherapy, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Tyler Walther (T)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Alexandra Snyder (A)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Matthew R Femia (MR)

Parker Institute for Cancer Immunotherapy, New York, NY, USA.
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Elizabeth A Comen (EA)

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weill Cornell Medical College, New York, NY, USA.

Hannah Y Wen (HY)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Matthew D Hellmann (MD)

Parker Institute for Cancer Immunotherapy, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weill Cornell Medical College, New York, NY, USA.

Niroshana Anandasabapathy (N)

Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
Department of Dermatology, Weill Cornell Medical College, New York, NY, USA.

Yong Liu (Y)

Department of Dermatology, Weill Cornell Medical College, New York, NY, USA.

Nasser K Altorki (NK)

Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.

Peter Lauer (P)

Aduro Biotech, Inc., Berkeley, CA, USA.

Olivier Levy (O)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Michael S Glickman (MS)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.

Jonathan Kaye (J)

Research Division of Immunology, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Doron Betel (D)

Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA.

Mary Philip (M)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mary.philip@vumc.org.
Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. mary.philip@vumc.org.

Andrea Schietinger (A)

Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. schietia@mskcc.org.
Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. schietia@mskcc.org.
Parker Institute for Cancer Immunotherapy, New York, NY, USA. schietia@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH